ImmuneCheckpointsAD SIGNED
Immune checkpoint blockade for fighting Alzheimer’s disease
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ImmuneCheckpointsAD project word cloud
Explore the words cloud of the ImmuneCheckpointsAD project. It provides you a very rough idea of what is the project "ImmuneCheckpointsAD" about.
Project "ImmuneCheckpointsAD" data sheet
The following table provides information about the project.
| Coordinator |
WEIZMANN INSTITUTE OF SCIENCE
Organization address contact info |
| Coordinator Country | Israel [IL] |
| Total cost | 2˙287˙500 € |
| EC max contribution | 2˙287˙500 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2016-ADG |
| Funding Scheme | ERC-ADG |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-06-01 to 2022-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | WEIZMANN INSTITUTE OF SCIENCE | IL (REHOVOT) | coordinator | 2˙287˙500.00 |
Map
Project objective
Understanding, and ultimately treating Alzheimer’s disease (AD) is a major need in Western countries. Currently, there is no available treatment to modify the disease. Several pioneering discoveries made by my team, attributing a key role to systemic immunity in brain maintenance and repair, and identifying unique interface between the brain’s borders through which the immune system assists the brain, led us to our recent discovery that transient reduction of systemic immune suppression could modify disease pathology, and reverse cognitive loss in mouse models of AD (Nature Communications, 2015; Nature Medicine, 2016; Science, 2014). This discovery emphasizes that AD is not restricted to the brain, but is associated with systemic immune dysfunction. Thus, the goal of addressing numerous risk factors that go awry in the AD brain, many of which are -as yet- unknown, could be accomplished by immunotherapy, using immune checkpoint blockade directed at the Programmed-death (PD)-1 pathway, to empower the immune system. In this proposal, we will adopt our new experimental paradigm to discover mechanisms through which the immune system supports the brain, and to identify key/novel molecular and cellular processes at various stages of the disease that are responsible for cognitive decline long before neurons are lost, and whose reversal or modification is needed to mitigate AD pathology, and prevent cognitive loss. Achieving our goals requires the multidisciplinary approaches and expertise at our disposal, including state-of-the art immunological, cellular, molecular, and genomic tools. The results will pave the way for developing a novel next-generation immunotherapy, by targeting additional selective immune checkpoint pathways, or identifying a specific immune-based therapeutic target, for prevention and treatment of AD. We expect that our results will help attain the ultimate goal of converting an escalating untreatable disease into a chronic treatable one.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Neta Rosenzweig, Raz Dvir-Szternfeld, Afroditi Tsitsou-Kampeli, Hadas Keren-Shaul, Hila Ben-Yehuda, Pierre Weill-Raynal, Liora Cahalon, Alex Kertser, Kuti Baruch, Ido Amit, Assaf Weiner, Michal Schwartz PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model published pages: , ISSN: 2041-1723, DOI: 10.1038/s41467-019-08352-5 |
Nature Communications 10/1 | 2020-02-13 |
| 2019 |
A. Kertser, K. Baruch, A. Deczkowska, A. Weiner, T. Croese, M. Kenigsbuch, I. Cooper, M. Tsoory, S. Ben-Hamo, I. Amit, M. Schwartz Corticosteroid signaling at the brain-immune interface impedes coping with severe psychological stress published pages: eaav4111, ISSN: 2375-2548, DOI: 10.1126/sciadv.aav4111 |
Science Advances 5/5 | 2020-02-13 |
| 2020 |
Michal Schwartz, Javier M. Peralta Ramos, Hila Ben-Yehuda A 20-Year Journey from Axonal Injury to Neurodegenerative Diseases and the Prospect of Immunotherapy for Combating Alzheimer’s Disease published pages: 243-250, ISSN: 0022-1767, DOI: 10.4049/jimmunol.1900844 |
The Journal of Immunology 204/2 | 2020-02-13 |
| 2018 |
Aleksandra Deczkowska, Ido Amit, Michal Schwartz Microglial immune checkpoint mechanisms published pages: 779-786, ISSN: 1097-6256, DOI: 10.1038/s41593-018-0145-x |
Nature Neuroscience 21/6 | 2019-10-09 |
| 2018 |
Aleksandra Deczkowska, Michal Schwartz Targeting neuro–immune communication in neurodegeneration: Challenges and opportunities published pages: 2702-2704, ISSN: 0022-1007, DOI: 10.1084/jem.20181737 |
The Journal of Experimental Medicine 215/11 | 2019-06-05 |
| 2018 |
Aleksandra Deczkowska, Hadas Keren-Shaul, Assaf Weiner, Marco Colonna, Michal Schwartz, Ido Amit Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration published pages: 1073-1081, ISSN: 0092-8674, DOI: 10.1016/j.cell.2018.05.003 |
Cell 173/5 | 2019-06-05 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNECHECKPOINTSAD" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IMMUNECHECKPOINTSAD" are provided by the European Opendata Portal: CORDIS opendata.